Reduced growth, increased vascular area, and reduced response to cisplatin in CD13-overexpressing human ovarian cancer xenografts.
D018262:Adenocarcinoma, Clear Cell / Q000378:metabolism; D002288:Adenocarcinoma, Mucinous / Q000378:metabolism; D000626:Aminopeptidases / Q000378:metabolism; D000818:Animals; D017209:Apoptosis; D018826:CD13 Antigens / Q000096:biosynthesis*; D002448:Cell Adhesion; D002455:Cell Division; D045744:Cell Line, Tumor; D002462:Cell Membrane / Q000378:metabolism; D002945:Cisplatin / Q000494:pharmacology*; D003094:Collagen / Q000494:pharmacology; D018284:Cystadenocarcinoma, Serous / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007797:Laminin / Q000494:pharmacology; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D010957:Plasmids / Q000378:metabolism; D011509:Proteoglycans / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016196:S Phase; D013997:Time Factors; D014162:Transfection
D004338:Drug Combinations; D007797:Laminin; D011509:Proteoglycans; D012333:RNA, Messenger; C059485:matrigel; D003094:Collagen; D000626:Aminopeptidases; D018826:CD13 Antigens; D002945:Cisplatin